Navigation Links
MEDRAD Installs First Intego(TM) PET Infusion System

WARRENDALE, Pa., Aug. 7 /PRNewswire/ -- MEDRAD, INC., announced today the first installation of its Intego(TM) PET Infusion System at the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center. To achieve this milestone, MEDRAD has partnered with IBA Molecular which will supply UPMC with Fluorodeoxyglucose (FDG) in a multi-dose vial housed in a specially-designed Tungsten vial shield. Use of this innovative system minimizes the need to manually prepare and handle individual FDG doses, significantly reducing potential radiation exposure to hospital personnel.

(Logo: )

The Intego System automates the administration of FDG for Positron Emission Tomography/Computed Tomography (PET/CT) imaging procedures. By automating and controlling FDG dosing and infusion, the Intego System precisely, flexibly, safely, and easily administers FDG to patients throughout the day.

The Intego System automatically extracts a patient dose from a multi-dose vial and administers the dose, via infusion, directly to the patient, minimizing the need for manual dose preparation and associated handling, as well as protecting the technologist from the corresponding radiation exposure. With the Intego System's dose-on-demand capability, the prescribed dose may be administered when the patient and technologist are ready, enabling technologists to easily and efficiently respond to schedule changes, patient delays, and add-on patients.

"MEDRAD will improve the quality of healthcare for patients and will enhance procedure safety for clinicians at Intego's first clinical site, UPMC, Hillman Cancer Center. The partnership with IBA Molecular helps us achieve this part of our mission," said Doug Descalzi, executive director, MEDRAD Molecular Imaging.

"IBA is very pleased to support this first clinical installation of the Intego System. We are excited to be a part of improving the way FDG is delivered and administered. This innovation will improve safety for technologists and physicians performing Positron Emission Tomography," said Anwer Rizvi, president, IBA Molecular.

MEDRAD recently received U.S. FDA 510(k) clearance for the Intego PET Infusion System.


MEDRAD, INC., is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2007 revenues were $525 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The company's world headquarters is near Pittsburgh, Pennsylvania, in the United States. MEDRAD is an affiliate of Bayer AG. For more information, visit

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at

About IBA Molecular

IBA Molecular is a committed partner in molecular imaging. Offering a global distribution of the most advanced cyclotron solutions, the most reliable radiopharmaceutical distribution network and the most novel research radionuclides, so that together we can make a difference in the lives of patients. Contact us to learn how our superior service, superior solutions and superior science can help build your PET business.

Cautionary statement regarding forward-looking statement.

Certain statements in this press release that are neither reported financial results nor other historical information are forward-looking statements, including but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results and MEDRAD's plans and objectives to differ materially from those expressed or implied in the forward-looking statements. MEDRAD, INC., undertakes no obligation to update publicly or revise any of these forward-looking statements, whether to reflect new information or future events or circumstances or otherwise.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
2. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
3. MEDRAD, Battelle Win Medical Design Excellence Award for MEDRAD XDS(TM) Extravasation Detector
4. MEDRAD(R) XDS(TM) Extravasation Detector Wins Medical Design Excellence Award
5. MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System
6. Tasker Products Installs Scalder Application at New Poultry Processors Facility
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
9. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
10. Genmab Announces 2007 First Half Year Results
11. Pharsight Achieves First License Sale for Public-Source Database
Post Your Comments:
(Date:10/13/2015)... NC (PRWEB) , ... October 13, 2015 , ... ... intensity focused ultrasound (HIFU) technologies, announced today that it received de novo clearance ... in the U.S. for the ablation of prostate tissue. Sonablate® is the ...
(Date:10/12/2015)... BRUSSELS , Oct. 12, 2015  Amgen ... presented additional findings from an exploratory sub-study of the previously ... presented today in an oral plenary session at the American ... in Seattle . 2 ... The small exploratory sub-study data showed that, at month 12, ...
(Date:10/12/2015)... Oct. 12, 2015  Rebiotix Inc. today announced ... designated its lead Microbiota Restoration Therapy (MRT) RBX2660 ... recurrent Clostridium difficile (C diff) infection, ... causes 29,000 deaths in the U.S. annually. 1 ... that was founded to revolutionize the treatment of ...
(Date:10/12/2015)... , Oct. 12, 2015  Patara Pharma, ... allergic and inflammatory diseases and conditions, today announced ... preferred stock financing. Concurrent with the close of ... into a Loan and Security Agreement with Silicon ... to $7 million. Patara will use the funds ...
Breaking Biology Technology:
(Date:10/9/2015)... 09 2015 ... the "Samsung Galaxy S6 Fingerprint Sensor ... their offering. --> ) ... "Samsung Galaxy S6 Fingerprint Sensor - Reverse ... --> Research and Markets ( ...
(Date:10/8/2015)... OXFORD, Connecticut , October 8, 2015 /PRNewswire/ ... ) ("NXT-ID" or the "Company"), a biometric authentication ... and creator of the Wocket® smart wallet announces ... 30, 2015 were approximately $410,000 compared with $113,00 ... Revenues for the 9 months ended September 30, ...
(Date:10/6/2015)... 6, 2015 Track Group, Inc. (OTCQX: TRCK), ... has signed a contract with the Virginia Department of ... range of sentences under the Department,s oversight. ... "This contract with the Virginia DOC will expand our ... advances our position as a trusted leader in offender ...
Breaking Biology News(10 mins):